Futura Medical PLC's (LON:FUM) Ken James speaks to Proactive London's Andrew Scott after announcing it's submitted the product dossier for its treatment of erectile dysfunction known as MED3000 for marketing approval in Europe.

In the US, James says that after a second pre-submission meeting with the US Food and Drug Administration (FDA), a pathway to US marketing approval for MED3000 has been established.

свернуть